Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHAITALI SINGH NANGIA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1669425286
CMS profile
894263
Location
COSTA MESA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$22,481.86

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHAITALI SINGH NANGIA

NPI 1669425286 · CMS profile ID 894263

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

COSTA MESA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669425286?year=2020&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHAITALI SINGH NANGIA, NPI 1669425286, CMS profile ID 894263. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669425286?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CHAITALI SINGH NANGIA, NPI 1669425286, CMS profile ID 894263. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669425286?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CHAITALI SINGH NANGIA, NPI 1669425286, CMS profile ID 894263, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1669425286?year=2020&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $22,481.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $23.1501/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751203333 CMS
E.R. Squibb & Sons, L.L.C. $18.3501/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727846809 CMS
PFIZER INC. $5.6001/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743765469 CMS
Lexicon Pharmaceuticals, Inc. $23.3901/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751838281 CMS
AstraZeneca Pharmaceuticals LP $14.6601/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736258765 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $94,620.54 184
PY2020 $22,481.86 105
PY2021 $78,504.30 134
PY2022 $86,950.83 161
PY2023 $124,612.45 150
PY2024 $158,853.80 121
PY2025 $131,218.69 86

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $453,013.97 128
PY2024 Principal investigator $201,017.41 21
PY2023 Principal investigator $160,924.81 7
PY2022 Principal investigator $168,687.91 6
PY2021 Principal investigator $260,000.00 1
PY2020 Principal investigator $10,946.62 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

128 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $752.00 12/31/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) No dispute reported 06/30/2026 1233739999
Principal investigator 1 Merck Sharp & Dohme LLC $35,345.48 12/31/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Earl No dispute reported 06/30/2026 1232924402
Principal investigator 1 Merck Sharp & Dohme LLC $17,540.72 12/31/2025 Non-covered Recipient Entity
Hoag Memoriall Hospital Presbyterian
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 1232926845
Principal investigator 1 PFIZER INC. $1,382.40 12/31/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228745204
Principal investigator 1 PFIZER INC. $2,447.56 12/27/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228733009
Principal investigator 1 PFIZER INC. $7,419.60 12/13/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228738203
Principal investigator 1 PFIZER INC. $22.50 12/04/2025 Non-covered Recipient Entity
Hoag Memorial Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716351
Principal investigator 1 PFIZER INC. $6,050.70 11/26/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228738547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $492.00 11/14/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184261389
Principal investigator 1 PFIZER INC. $1,981.80 11/04/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228728825
Principal investigator 1 PFIZER INC. $15.00 11/03/2025 Non-covered Recipient Entity
Hoag Memorial Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716523
Principal investigator 1 Day One Biopharmaceuticals $363.29 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091731
Principal investigator 1 Day One Biopharmaceuticals $883.31 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091733
Principal investigator 1 Day One Biopharmaceuticals $438.61 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091735
Principal investigator 1 Day One Biopharmaceuticals $438.61 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091737
Principal investigator 1 Day One Biopharmaceuticals $40.36 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091739
Principal investigator 1 Day One Biopharmaceuticals $48.74 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091741
Principal investigator 1 Day One Biopharmaceuticals $438.61 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091743
Principal investigator 1 Day One Biopharmaceuticals $363.29 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091745
Principal investigator 1 Day One Biopharmaceuticals $48.74 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091747
Principal investigator 1 Day One Biopharmaceuticals $40.36 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091749
Principal investigator 1 Day One Biopharmaceuticals $48.74 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091751
Principal investigator 1 Day One Biopharmaceuticals $438.61 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091753
Principal investigator 1 Day One Biopharmaceuticals $48.74 10/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
Subprotocol of DAY101 in Combination with Pimasertib No dispute reported 06/30/2026 1240091755
Principal investigator 1 PFIZER INC. $114,601.20 10/21/2025 Non-covered Recipient Entity
Hoag Memorial Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716349
Principal investigator 1 PFIZER INC. $15.00 10/21/2025 Non-covered Recipient Entity
Hoag Memorial Hospital
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716415
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $665.00 09/30/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) No dispute reported 06/30/2026 1233739997
Principal investigator 1 PFIZER INC. $2,396.25 09/24/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228761111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $943.00 09/23/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184241682
Principal investigator 1 PFIZER INC. $37,642.35 08/23/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228765943
Principal investigator 1 PFIZER INC. $2,250.00 08/05/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228785204
Principal investigator 1 PFIZER INC. $5,142.15 07/26/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228784107
Principal investigator 1 PFIZER INC. $750.00 07/01/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228764006
Principal investigator 1 PFIZER INC. $16,301.40 06/26/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228724450
Principal investigator 1 Day One Biopharmaceuticals $1,000.00 06/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091175
Principal investigator 1 Day One Biopharmaceuticals $1,000.00 06/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091177
Principal investigator 1 Day One Biopharmaceuticals $1,000.00 06/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091179
Principal investigator 1 Day One Biopharmaceuticals $438.61 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091091
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091093
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091095
Principal investigator 1 Day One Biopharmaceuticals $438.61 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091097
Principal investigator 1 Day One Biopharmaceuticals $98.14 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091099
Principal investigator 1 Day One Biopharmaceuticals $438.61 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091101
Principal investigator 1 Day One Biopharmaceuticals $438.61 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091103
Principal investigator 1 Day One Biopharmaceuticals $438.61 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091105
Principal investigator 1 Day One Biopharmaceuticals $438.61 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091107
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091109
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091111
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091113
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091115
Principal investigator 1 PFIZER INC. $9,467.55 05/14/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228765391
Principal investigator 1 PFIZER INC. $6,617.70 05/14/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228792986
Principal investigator 1 Day One Biopharmaceuticals $504.23 05/08/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091057
Principal investigator 1 Day One Biopharmaceuticals $56.02 05/08/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091059
Principal investigator 1 Day One Biopharmaceuticals $560.25 05/08/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091061
Principal investigator 1 Day One Biopharmaceuticals $504.23 05/08/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091063
Principal investigator 1 Day One Biopharmaceuticals $56.02 05/08/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091065
Principal investigator 1 PFIZER INC. $3,250.00 05/06/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228771800
Principal investigator 1 PFIZER INC. $8,511.40 05/06/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228773262
Principal investigator 1 Day One Biopharmaceuticals $158.22 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090917
Principal investigator 1 Day One Biopharmaceuticals $138.51 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090933
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090955
Principal investigator 1 Day One Biopharmaceuticals $915.05 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090965
Principal investigator 1 Day One Biopharmaceuticals $158.22 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090967
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090969
Principal investigator 1 Day One Biopharmaceuticals $169.70 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090971
Principal investigator 1 Day One Biopharmaceuticals $55.08 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090973
Principal investigator 1 Day One Biopharmaceuticals $757.23 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090975
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090977
Principal investigator 1 Day One Biopharmaceuticals $226.80 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090979
Principal investigator 1 Day One Biopharmaceuticals $232.47 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090981
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090983
Principal investigator 1 Day One Biopharmaceuticals $84.78 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090985
Principal investigator 1 Day One Biopharmaceuticals $56.02 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090987
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090989
Principal investigator 1 Day One Biopharmaceuticals $158.22 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090991
Principal investigator 1 Day One Biopharmaceuticals $56.02 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090993
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090995
Principal investigator 1 Day One Biopharmaceuticals $163.89 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090997
Principal investigator 1 Day One Biopharmaceuticals $203.44 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090999
Principal investigator 1 Day One Biopharmaceuticals $158.22 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091001
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091003
Principal investigator 1 Day One Biopharmaceuticals $163.89 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091005
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091007
Principal investigator 1 Day One Biopharmaceuticals $487.23 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091009
Principal investigator 1 Day One Biopharmaceuticals $158.22 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091011
Principal investigator 1 Day One Biopharmaceuticals $220.32 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091013
Principal investigator 1 Day One Biopharmaceuticals $599.55 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091015
Principal investigator 1 Day One Biopharmaceuticals $48.74 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091017
Principal investigator 1 Day One Biopharmaceuticals $158.22 05/05/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240091027
Principal investigator 1 Day One Biopharmaceuticals $504.23 05/01/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090907
Principal investigator 1 PFIZER INC. $650.00 05/01/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228765053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,250.00 04/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184183352
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,903.00 04/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184183354
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,341.00 04/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184183356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,800.00 04/15/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184183358
Principal investigator 1 PFIZER INC. $5,698.35 04/08/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228779951
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $328.90 03/30/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) No dispute reported 06/30/2026 1233739995
Principal investigator 1 PFIZER INC. $18,586.00 03/26/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228788323
Principal investigator 1 Day One Biopharmaceuticals $504.23 03/19/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090771
Principal investigator 1 PFIZER INC. $3,017.75 03/14/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228782970
Principal investigator 1 PFIZER INC. $2,840.60 02/22/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228761885
Principal investigator 1 AstraZeneca Pharmaceuticals LP $45,544.70 02/19/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185553375
Principal investigator 1 PFIZER INC. $3,390.00 02/14/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228742692
Principal investigator 1 Day One Biopharmaceuticals $438.61 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090647
Principal investigator 1 Day One Biopharmaceuticals $438.61 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090649
Principal investigator 1 Day One Biopharmaceuticals $438.61 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090651
Principal investigator 1 Day One Biopharmaceuticals $438.61 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090653
Principal investigator 1 Day One Biopharmaceuticals $438.61 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090655
Principal investigator 1 Day One Biopharmaceuticals $495.72 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090657
Principal investigator 1 Day One Biopharmaceuticals $438.61 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090659
Principal investigator 1 Day One Biopharmaceuticals $438.61 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090661
Principal investigator 1 Day One Biopharmaceuticals $438.61 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090663
Principal investigator 1 Day One Biopharmaceuticals $438.61 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090665
Principal investigator 1 PFIZER INC. $16,951.90 02/05/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228759786
Principal investigator 1 PFIZER INC. $3,520.00 01/22/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228760259
Principal investigator 1 PFIZER INC. $1,151.18 01/22/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228762424
Principal investigator 1 Janssen Research & Development, LLC $10,000.00 01/21/2025 Non-covered Recipient Entity
Hoag Meml Hosp Presby
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC No dispute reported 06/30/2026 1175174131
Principal investigator 1 Janssen Research & Development, LLC $300.00 01/21/2025 Non-covered Recipient Entity
Hoag Meml Hosp Presby
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC No dispute reported 06/30/2026 1175174194
Principal investigator 1 PFIZER INC. $3,445.20 01/15/2025 Non-covered Recipient Entity
Hoag Memorial Hospital Presbyterian
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228801883
Principal investigator 1 Day One Biopharmaceuticals $225.00 01/02/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090411
Principal investigator 1 Day One Biopharmaceuticals $225.00 01/02/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090413
Principal investigator 1 Day One Biopharmaceuticals $2,157.00 01/02/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090415
Principal investigator 1 Day One Biopharmaceuticals $225.00 01/02/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090417
Principal investigator 1 Day One Biopharmaceuticals $2,157.00 01/02/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090419
Principal investigator 1 Day One Biopharmaceuticals $2,157.00 01/02/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090421
Principal investigator 1 Day One Biopharmaceuticals $217.00 01/02/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090423
Principal investigator 1 Day One Biopharmaceuticals $217.00 01/02/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations No dispute reported 06/30/2026 1240090437